Literature DB >> 26464407

Not all ST-segment changes are myocardial injury: hypercalcaemia-induced ST-segment elevation.

Adam Orville Strand1, Thein Tun Aung2, Ajay Agarwal3.   

Abstract

ST-segment elevation myocardial infarction is an important, life-threatening diagnosis that requires quick diagnosis and management. We describe the case of an 83-year-old man with coronary artery disease, ischaemic cardiomyopathy with left ventricular ejection fraction of 15%, newly diagnosed multiple myeloma that had an initial ECG showing ST-segment elevation in anterior leads V1-3 and ST-segment depression in lateral leads concerning for an ST-segment elevation myocardial infarction. Troponins were negative and his calcium was 3.55 mmol/L. It was thought that the ECG changes were not indicative of cardiac ischaemia but, rather, hypercalcaemia. He was treated with fluids, diuretics and zolendronic acid, with subsequent resolution of ST-segment changes. This case demonstrates that one must consider disease other than myocardial ischaemia as the culprit of ST-segment changes if physical examination and history do not point towards myocardial injury, as unnecessary invasive revascularisation procedures have inherent risks. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26464407      PMCID: PMC4612722          DOI: 10.1136/bcr-2015-211214

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  38 in total

1.  Electrocardiographic findings in 67,375 asymptomatic subjects. X. Normal values.

Authors:  R G HISS; L E LAMB; M F ALLEN
Journal:  Am J Cardiol       Date:  1960-07       Impact factor: 2.778

2.  ST-segment elevation: a common finding in severe hypercalcemia.

Authors:  Laszlo Littmann; Lee Taylor; William D Brearley
Journal:  J Electrocardiol       Date:  2006-10-06       Impact factor: 1.438

3.  Acute myocardial infarction mimicking squamous cell lung cancer with bone metastases due to hypercalcemia: a case report.

Authors:  Chong-feng Fang; Geng Xu; Yang-xin Chen
Journal:  Chin Med J (Engl)       Date:  2010-02-05       Impact factor: 2.628

4.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner
Journal:  J Am Coll Cardiol       Date:  2012-09-05       Impact factor: 24.094

5.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Patrick T O'Gara; Frederick G Kushner; Deborah D Ascheim; Donald E Casey; Mina K Chung; James A de Lemos; Steven M Ettinger; James C Fang; Francis M Fesmire; Barry A Franklin; Christopher B Granger; Harlan M Krumholz; Jane A Linderbaum; David A Morrow; L Kristin Newby; Joseph P Ornato; Narith Ou; Martha J Radford; Jacqueline E Tamis-Holland; Jacqueline E Tommaso; Cynthia M Tracy; Y Joseph Woo; David X Zhao
Journal:  Circulation       Date:  2012-12-17       Impact factor: 29.690

6.  Extreme hypercalcemia and electrocardiographic changes.

Authors:  P S Douglas; K A Carmichael; P M Palevsky
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778

7.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.

Authors:  W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

8.  Conditions mimicking acute ST-segment elevation myocardial infarction in patients referred for primary percutaneous coronary intervention.

Authors:  Y L Gu; T Svilaas; I C C van der Horst; F Zijlstra
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

Review 9.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project.

Authors:  Thao Huynh; Jafna L Cox; David Massel; Cheryl Davies; Joseph Hilbe; Wayne Warnica; Paul A Daly
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.